PTGX: Protagonist Therapeutics, Inc.
About
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Current Value
$38.291 Year Return
Current Value
$38.291 Year Return
Key Details
Market Cap
$2.30B
P/E Ratio
14.5
1Y Stock Return
122.64%
1Y Revenue Growth
36565.08%
Dividend Yield
0.00%
Price to Book
4.3
Strategies that include PTGX
Stock's related to PTGX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VIR | 39.36% | $954.40M | -26.51% | 0.00% |
| CMPR | 39.00% | $1.94B | +7.37% | 0.00% |
| PGEN | 38.78% | $228.91M | -28.00% | 0.00% |
| FATE | 38.40% | $248.29M | -11.02% | 0.00% |
| VRDN | 38.19% | $1.60B | +28.92% | 0.00% |
| FOLD | 38.09% | $2.84B | -11.52% | 0.00% |
| RCKT | 37.71% | $1.20B | -39.83% | 0.00% |
| RCUS | 37.69% | $1.33B | +5.07% | 0.00% |
| SNDX | 37.54% | $1.35B | +2.87% | 0.00% |
| TWST | 37.44% | $2.42B | +74.27% | 0.00% |
| NEU | 37.19% | $5.13B | +3.54% | 1.82% |
| BEAM | 36.97% | $2.09B | -9.52% | 0.00% |
| ALEC | 36.94% | $377.04M | -19.46% | 0.00% |
| CCS | 36.90% | $2.69B | +20.00% | 1.19% |
| PLYM | 36.75% | $842.88M | -11.32% | 5.12% |
| CRNX | 36.16% | $5.12B | +84.27% | 0.00% |
| RPTX | 36.13% | $122.43M | -39.50% | 0.00% |
| BRSP | 35.87% | $806.64M | -3.86% | 12.20% |
| ALE | 35.80% | $3.73B | +17.43% | 4.38% |
| OMER | 35.35% | $349.44M | +258.93% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| IMAX | -0.03% | $1.31B | +51.92% | 0.00% |
| VTLE | 0.03% | $1.19B | -32.18% | 0.00% |
| EIG | 0.07% | $1.30B | +38.83% | 2.25% |
| SCKT | -0.08% | $10.88M | +15.32% | 0.00% |
| SRG | -0.08% | $221.13M | -55.94% | 0.00% |
| CARV | 0.16% | $8.48M | -8.79% | 0.00% |
| STVN | 0.16% | $4.95B | -32.48% | 0.32% |
| LICY | 0.18% | $53.41M | -60.56% | 0.00% |
| OCX | 0.19% | $42.93M | -36.09% | 0.00% |
| KNOP | 0.20% | $210.40M | +11.75% | 1.68% |
| SUZ | -0.21% | $13.00B | -2.96% | 2.27% |
| CNA | -0.22% | $13.16B | +23.03% | 3.61% |
| PRT | -0.24% | $48.72M | -16.56% | 10.33% |
| GIS | 0.26% | $34.85B | -2.91% | 3.78% |
| PG | 0.27% | $402.15B | +14.14% | 2.33% |
| TEN | 0.31% | $606.64M | +3.32% | 4.39% |
| VIRC | 0.33% | $253.30M | +129.35% | 0.53% |
| ALAR | 0.36% | $89.09M | +158.08% | 0.00% |
| GOGL | -0.37% | $2.39B | +35.11% | 8.40% |
| LITB | 0.38% | $35.48M | -75.45% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HUSA | -13.27% | $16.69M | -11.56% | 0.00% |
| NEUE | -12.46% | $40.93M | -34.13% | 0.00% |
| BTCT | -11.69% | $42.61M | +353.33% | 0.00% |
| SAVA | -11.46% | $1.35B | +25.50% | 0.00% |
| PRPO | -10.50% | $9.10M | -13.65% | 0.00% |
| TPST | -9.92% | $37.75M | -77.59% | 0.00% |
| PGR | -9.36% | $149.10B | +57.29% | 0.45% |
| AFL | -8.57% | $61.74B | +35.69% | 1.35% |
| STG | -8.56% | $35.67M | +7.92% | 0.00% |
| MCK | -8.38% | $78.15B | +35.51% | 0.42% |
| AMBC | -8.37% | $584.50M | -17.09% | 0.00% |
| LPTH | -8.16% | $62.27M | +33.05% | 0.00% |
| WRB | -7.80% | $22.94B | +29.98% | 0.69% |
| UNM | -7.64% | $13.16B | +69.20% | 2.16% |
| UUU | -7.50% | $4.97M | -41.89% | 0.00% |
| NKE | -7.45% | $110.02B | -30.63% | 2.01% |
| RNR | -7.06% | $13.74B | +23.09% | 0.58% |
| SBLK | -6.88% | $2.38B | +2.30% | 10.64% |
| SFL | -6.30% | $1.55B | -4.05% | 9.77% |
| MRO | -5.74% | $16.08B | +13.59% | 1.53% |
ETF's related to PTGX
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 54.62% | $6.58B | 0.35% |
| PTH | 50.23% | $143.31M | 0.6% |
| IBB | 50.02% | $6.66B | 0.45% |
| GNOM | 47.92% | $70.59M | 0.5% |
| PBE | 46.47% | $258.53M | 0.58% |
| BBH | 44.27% | $397.87M | 0.35% |
| FBT | 44.24% | $1.11B | 0.56% |
| ARKG | 44.19% | $1.13B | 0.75% |
| FHLC | 43.29% | $2.73B | 0.084% |
| IWC | 42.13% | $933.99M | 0.6% |
| VHT | 41.98% | $17.06B | 0.1% |
| RSPH | 41.89% | $885.96M | 0.4% |
| XPH | 41.43% | $157.87M | 0.35% |
| IWO | 40.96% | $12.56B | 0.24% |
| SMMV | 40.31% | $321.07M | 0.2% |
| PSC | 40.23% | $702.17M | 0.38% |
| VB | 40.22% | $63.63B | 0.05% |
| IYH | 40.01% | $3.19B | 0.39% |
| ISCG | 39.98% | $640.00M | 0.06% |
| VTWO | 39.48% | $12.38B | 0.1% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBIL | 0.05% | $637.70M | 0.15% |
| COMT | 0.32% | $829.06M | 0.48% |
| BILZ | 0.42% | $563.02M | 0.14% |
| KCCA | 0.59% | $220.51M | 0.87% |
| DBE | -0.76% | $50.13M | 0.77% |
| DBB | -0.76% | $126.37M | 0.77% |
| WEAT | 0.77% | $120.27M | 0.28% |
| PDBC | 0.91% | $4.40B | 0.59% |
| GSG | 1.07% | $914.42M | 0.75% |
| DBC | 1.13% | $1.39B | 0.87% |
| SOYB | -1.19% | $27.32M | 0.22% |
| BOXX | 1.41% | $4.43B | 0.1949% |
| HIGH | -1.51% | $302.78M | 0.51% |
| DUSB | 1.71% | $797.63M | 0.15% |
| HDRO | -1.85% | $164.26M | 0.3% |
| SGOV | 2.02% | $27.53B | 0.09% |
| FMF | 2.71% | $244.61M | 0.95% |
| TBIL | 2.91% | $4.38B | 0.15% |
| IAK | 3.08% | $760.79M | 0.39% |
| FTGC | 3.21% | $2.17B | 1.02% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -23.82% | $388.04M | 1.43% |
| VIXY | -22.20% | $195.31M | 0.85% |
| USDU | -19.59% | $201.97M | 0.5% |
| UUP | -16.39% | $309.25M | 0.77% |
| CTA | -14.74% | $350.27M | 0.78% |
| USCI | -10.81% | $185.47M | 1.07% |
| DBO | -10.18% | $217.57M | 0.77% |
| TPMN | -10.13% | $40.60M | 0.65% |
| CANE | -8.57% | $17.72M | 0.29% |
| KMLM | -7.69% | $353.87M | 0.9% |
| AGZD | -7.47% | $142.76M | 0.23% |
| EQLS | -7.19% | $76.08M | 1% |
| DBA | -5.67% | $755.88M | 0.93% |
| MINT | -4.68% | $11.62B | 0.35% |
| CORN | -4.67% | $61.12M | 0.2% |
| KRBN | -3.88% | $242.47M | 0.85% |
| TAIL | -3.23% | $67.98M | 0.59% |
| HDRO | -1.85% | $164.26M | 0.3% |
| HIGH | -1.51% | $302.78M | 0.51% |
| SOYB | -1.19% | $27.32M | 0.22% |
News
Finnhub
NEWARK - Protagonist Therapeutics, Inc. today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in...
Yahoo
ICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16; 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24 ICONIC-TOTAL achieved its primary endpoint of IGA score of 0 or 1 at week 16 in patients ...
Finnhub
Protagonist announces positive topline results from Phase 3 ICONIC studies of icotrokinra in plaque psoriasis, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23...
Yahoo
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 8.47% and 3.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
NEWARK, Calif. AP) — Protagonist Therapeutics Inc. PTGX) on Thursday reported a loss of $33.2 million in its third quarter.
Yahoo
Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024 Top line results for JNJ-2113 Phase 2b ANTHEM clinical trial in moderate to severe ulcerative ...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.